Peapod Lane Capital’s enGene Therapeutics ENGN Stock Holding History

Peapod Lane Capital’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Buy	+1,102,149	New	+$4.49M	1.29%	37

Other funds holding ENGN

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Fountainhead AM Warren, New Jersey $135M AUM 24.26% 1-Year Est. Return

PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Peapod Lane Capital's ENGN Position: Q2 2026 in Review

Peapod Lane Capital opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 1,102,149 shares worth $1.91M. The stake represents 1.29% of the portfolio and ranks #37 among its holdings.

11 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Peapod Lane Capital held 1,102,149 shares of enGene Therapeutics worth $1.91M as of Q2 2026.
enGene Therapeutics was a new Peapod Lane Capital position in Q2 2026.
enGene Therapeutics made up 1.29% of Peapod Lane Capital's portfolio in Q2 2026, its #37 holding.
11 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.